Orchid Pharma received US FDA approval for two drugs

The drugs to treat dementia and control hypertension gets ANDA approval, said the company

BS Reporter Chennai
Last Updated : Jun 12 2015 | 8:14 PM IST
Chennai-based Orchid Chemicals and Pharmaceuticals Ltd (OCPL) has received US Food and Drug Administartion's approval for its generic form of dementia drug Rivastigmine Capsules and hypertension drug Felodipine extended release tablets of various strengths.

The company today informed the National Stock Exchange (NSE) that it has received approval for the Abbreviated New Drug Application (ANDA) for Rivastigmine Capsules in 1.5 mg, 3 mg, 4.5 mg and 6 mg and Felodipine extended release tablets in three strengths including 5 mg and 10 mg.

ALSO READ: SBI appoints its former deputy MD as nominee on Orchid Pharma board

 

According to information available, Rivastigmine is used for treatment of memory problems associated with Alzheimer's disease and with Parkinson's disease. Swiss pharma major Novartis has its brand Exelon with this ingredient. Felodipine extended release is used to control High blood pressure and has been marketed by AstraZeneca and Sanofi Aventis under the brand names Plendil and Renedil, respectively.

 

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jun 12 2015 | 8:00 PM IST

Next Story